注释ID

1451136500

变量_单倍型

NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A

基因

NAT2

药物名称(英)

hydralazine

药物名称(中)

肼屈嗪

PMID

24702251

类型

Metabolism/PK

含义

not stated

记事

Rapid acetylators were given a higher dose. The average means  SE of AUC0-inf and Cmax in fast (given dose 182 mg) and slow acetylators (given dose 83 mg) were 1583 +/- 243 and 1696 +/- 197 ng h/mL, 93
4  6
8 and 112
5  17
2 ng/mL, respectively. None of the determined and calculated parameters was significantly different (a = 0
05) between the two groups. Three SNPs (rs1801280, rs1799930 and rs1799931) were chosen as tag SNPs for NAT2 alleles with reduced activity (NAT2*5, *6 and *7). *4 seemed to be assigned in the absence of *5, *6, *7.

专家论述

NAT2 *5D/*5D + *5D/*6B + *5D/*7A (assigned as slow acetylator phenotype) are associated with decreased metabolism of hydralazine in healthy individuals as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .

等位基因

*5D/*5D + *5D/*6B + *5D/*7A

专家评论

备注

变体注释摘要

id	研究类型	特征类型
17865	cohort	Study Cohort